Edition:
India

Biofrontera AG (BFRA.OQ)

BFRA.OQ on NASDAQ Stock Exchange Capital Market

8.91USD
18 Sep 2020
Change (% chg)

$0.03 (+0.34%)
Prev Close
$8.88
Open
$8.78
Day's High
$8.91
Day's Low
$8.65
Volume
11,545
Avg. Vol
125,475
52-wk High
$55.00
52-wk Low
$5.40

Latest Key Developments (Source: Significant Developments)

Biofrontera Has Reached Mutual Agreement With Wilhelm K.T. Zours And Deutsche Balaton AG
Friday, 11 Sep 2020 

Sept 11 (Reuters) - BIOFRONTERA AG ::PLANS MEDIATION TO RESOLVE (LEGAL) DISPUTES.HAS REACHED A MUTUAL AGREEMENT WITH MR. WILHELM K.T. ZOURS (NOT WILHELM K.T. ZOU) AND DEUTSCHE BALATON AG .COMPLETION OF MEDIATION AGREEMENT IS EXPECTED TODAY.HAS REACHED A MUTUAL AGREEMENT WITH MR. WILHELM K.T. ZOURS AND DEUTSCHE BALATON AG ON KEY ELEMENTS OF A MEDIATION AGREEMENT.  Full Article

Biofrontera Q1 Consolidated Sales Down At EUR 6.5 Mln
Tuesday, 19 May 2020 

May 19 (Reuters) - BIOFRONTERA AG ::Q1 CONSOLIDATED SALES OF 6.5 MILLION EUROS REFLECT A DECREASE OF 5% COMPARED TO SAME PERIOD LAST YEAR..UNABLE AT THIS POINT TO MAKE ANY RELIABLE FORECASTS REGARDING COURSE OF BUSINESS IN 2020 THAT GO BEYOND STATEMENTS MADE IN ANNUAL REPORT..Q1 LOSS AFTER TAX 6.082 MILLION EUR VERSUS LOSS 2.980 MILLION EUR YEAR AGO.Q1 LOSS BEFORE TAX EUR 5.498 MILLION VERSUS LOSS EUR 2.637 MILLION YEAR AGO.  Full Article

Biofrontera Files Label Extension For Ameluz In EU To Include Treatment Of Actinic Keratosis On Extremities And Trunk/Neck
Tuesday, 17 Sep 2019 

Sept 17 (Reuters) - Biofrontera AG ::BIOFRONTERA FILES LABEL EXTENSION FOR AMELUZ® IN EU TO INCLUDE TREATMENT OF ACTINIC KERATOSIS ON EXTREMITIES AND TRUNK/NECK.BIOFRONTERA AG - STUDY MET ITS PRIMARY ENDPOINT WITH AN AVERAGE LESION HEALING RATE PER PATIENT SIDE OF 86% FOR AMELUZ.BIOFRONTERA AG - SUBMISSION FOLLOWS POSITIVE TREATMENT OUTCOMES DEMONSTRATED FOR AMELUZ(® )IN RECENT PHASE III TRIAL.BIOFRONTERA AG - HAS ALSO ENTERED INTO DISCUSSIONS WITH U.S. FOOD AND DRUG ADMINISTRATION FOR APPROVAL IN U.S..BIOFRONTERA AG - ALSO ENTERED INTO DISCUSSIONS WITH U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR APPROVAL IN U.S..  Full Article

Biofrontera H1 Net Result Of EUR 8.6 Mln
Tuesday, 27 Aug 2019 

Aug 27 (Reuters) - BIOFRONTERA AG ::H1 TOTAL REVENUE INCREASED 55% TO EUR 13.9 MILLION COMPARED TO EUR 9.0 MILLION.H1 NET RESULT OF EUR 8.6 MILLION.CASH AND CASH EQUIVALENTS AMOUNTED TO EUR 21.6 MILLION AS OF JUNE 30, 2019, COMPARED TO EUR 19.5 MILLION AS OF DECEMBER 31, 2018.CURRENTLY EXPECTING ITS ANNUAL REVENUE TO BE IN RANGE OF EUR 32 AND 35 MILLION.EXPECTATION FOR FY REVENUE IS SLIGHTLY BELOW PREVIOUS GUIDANCE, WHICH TARGETED EUR 35 TO 40 MILLION.ADJUSTED GUIDANCE IS PRIMARILY ATTRIBUTABLE TO CONTINUED DYNAMIC BUT SLIGHTLY WEAKER GROWTH IN US.CONTINUES TO EXPECT TO REACH OPERATING BREAK-EVEN DURING Q4 OF 2019.EXPECTS TOTAL SALES FROM ITS NEW PRODUCTS OF AROUND EUR 1 TO 1.5 MILLION IN 2019.  Full Article

Biofrontera Provides Update On Cutanea Integration
Monday, 5 Aug 2019 

Aug 5 (Reuters) - BIOFRONTERA AG ::PROVIDES UPDATE ON CUTANEA INTEGRATION.ACQUIRED 100% OF STOCK OF CUTANEA, A SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON DERMATOLOGY PRODUCTS, FROM MARUHO CO., LTD..ON MARCH 25, 2019, BIOFRONTERA INC. THROUGH ITS WHOLLY OWNED SUBSIDIARY BIOFRONTERA NEWDERM LLC, ACQUIRED CUTANEA.AGREED TO PROVIDE AMOUNT OF UP TO USD $7.3 MILLION AS START-UP COSTS TO COVER ANY INCREMENTAL COSTS FROM BUSINESS ACTIVITIES.PROFITS FROM SALE OF CUTANEA PRODUCTS WILL BE EQUALLY SHARED BETWEEN MARUHO AND BIOFRONTERA UNTIL 2030.DEFERRED PURCHASE PRICE EQUALING ACTUAL START-UP COSTS REQUESTED BY BIOFRONTERA SHALL BE PAYABLE TO MARUHO BY JAN 2023.  Full Article

Biofrontera AG H1 Sales Of About EUR 13.8-14.0 Mln
Tuesday, 9 Jul 2019 

July 9 (Reuters) - Biofrontera AG ::DGAP-NEWS: BIOFRONTERA AG: BIOFRONTERA REPORTS PRELIMINARY UNAUDITED SALES REVENUE FOR THE FIRST SIX MONTHS OF 2019.H1 SALES OF ABOUT EUR 13.8 TO 14.0 MILLION.H1 SALES OF AMELUZ IN U.S. WERE BETWEEN EUR 9.5 AND 9.7 MILLION, COMPARED TO EUR 6.4 MILLION (+50%) YEAR AGO.REVENUE IN GERMANY INCREASED BY ABOUT 82% TO EUR 2.1 TO 2.2 MILLION IN FIRST HALF OF 2019.  Full Article

Biofrontera Removes AGM Agenda Item Including Dr. Granzer's Removal From Supervisory Board
Friday, 5 Jul 2019 

July 5 (Reuters) - BIOFRONTERA AG ::DISMISSING AGM AGENDA ITEM 10 (INCLUDING THE REMOVAL OF DR. GRANZER FROM THE SUPERVISORY BOARD).IF UNDER ITEM 11 OF AGENDA DR. ING. BORER IS REMOVED FROM SUPERVISORY BOARD, TO PROPOSE PROF. DR. FRANCA RUHWEDEL TO SUCCEED DR. BORER.  Full Article

Biofrontera: Board Recommends Not To Accept Deutsche Balaton And Delphi Offer
Monday, 1 Jul 2019 

July 2 (Reuters) - Biofrontera AG ::SAID ON MONDAY IN A JOINT STATEMENT, EXECUTIVE BOARD AND MANAGEMENT BOARD OF BIOFRONTERA AG RECOMMEND NOT TO ACCEPT THE PARTIAL ACQUISITION OFFER OF DEUTSCHE BALATON BIOTECH AG AND DELPHI UNTERNEHMENSBERATUNG AKTIENGESELLSCHAFT.THE EMPLOYEES OF BIOFRONTERA AG ALSO REJECT THE PARTIAL ACQUISITION OFFER OF DEUTSCHE BALATON BIOTECH AG AND DELPHI UNTERNEHMENSBERATUNG AKTIENGESELLSCHAFT IN AN OWN STATEMENT.  Full Article

DB Biotech, Delphi Hike Offer For Biofrontera Shares
Monday, 1 Jul 2019 

July 1 (Reuters) - Deutsche Balaton's Deutsche Balaton Biotech AG::SAYS DEUTSCHE BALATON BIOTECH AG, DELPHI UNTERNEHMENSBERATUNG AG DECIDE TO RAISE OFFER PRICE FOR BIOFRONTERA AG B8FGN.DE SHARES.SAYS NOW OFFERING 8 EUR IN CASH FOR EACH BIOFRONTERA SHARE.SAYS NEW OFFER PRICE FOR UP TO 500,000 SHARES IN BIOFRONTERA IS 11% ABOVE RIVAL OFFER BY MARUHO DEUTSCHLAND GMBH.  Full Article

Biofrontera Q1 Prelim Revenue At About EUR 6.8 Million
Monday, 15 Apr 2019 

April 15 (Reuters) - Biofrontera AG ::DGAP-NEWS: BIOFRONTERA AG: BIOFRONTERA REPORTS PRELIMINARY UNAUDITED SALES REVENUE FOR THE FIRST THREE MONTHS OF 2019.PRELIMINARY UNAUDITED REVENUE OF COMPANY FOR PERIOD JANUARY TO MARCH 2019 WAS AROUND EUR 6.8 MILLION.Q1 PRELIMINARY UNAUDITED PRODUCT SALES IN U.S. ARE EXPECTED TO BE ABOUT EUR 5.2 MILLION, VERSUS EUR 3.4 MILLION YEAR AGO.  Full Article

BRIEF-Biofrontera Confirms Financing Need

* THERE IS A FINANCING NEED OF AT LEAST EUR 5 MILLION TO MAINTAIN BUSINESS OPERATIONS UNTIL END OF APRIL 2021